• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在 KDIGO 慢性肾脏病脂质指南前后使用他汀类药物:基于人群的中断时间序列分析。

Statin use before and after the KDIGO Lipids in chronic kidney disease guideline: A population-based interrupted time series analysis.

机构信息

Internal Medicine Research Unit, University Hospital of Southern Denmark, Odense, Denmark.

Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.

出版信息

Basic Clin Pharmacol Toxicol. 2022 Nov;131(5):306-310. doi: 10.1111/bcpt.13768. Epub 2022 Jul 16.

DOI:10.1111/bcpt.13768
PMID:35762022
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9795967/
Abstract

In November 2013, the Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease was published, recommending statins for all individuals 50 years or older with an estimated glomerular filtration rate below 60 ml/min/1.73 m to lower the risk of major cardiovascular events. We quantified the prevalence of statin use among the target population before and after the guideline publication in a large Danish cohort of individuals with an estimated glomerular filtration rate below 60 ml/min/1.73 m , to investigate the effect of the guideline, but found no difference in the prevalence of statin use prior to and after the guideline publication.

摘要

2013 年 11 月,《改善全球肾脏病预后组织肾脏病临床实践指南:脂质管理》发表,建议所有年龄 50 岁及以上、估算肾小球滤过率(eGFR)低于 60ml/min/1.73m2 的患者使用他汀类药物,以降低主要心血管事件的风险。我们在一个 eGFR 低于 60ml/min/1.73m2 的大型丹麦队列中,对目标人群在指南发布前后使用他汀类药物的情况进行了量化,以调查该指南的效果,但在指南发布前后,他汀类药物的使用比例没有差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9795967/725308294c09/BCPT-131-306-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9795967/725308294c09/BCPT-131-306-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9795967/725308294c09/BCPT-131-306-g001.jpg

相似文献

1
Statin use before and after the KDIGO Lipids in chronic kidney disease guideline: A population-based interrupted time series analysis.在 KDIGO 慢性肾脏病脂质指南前后使用他汀类药物:基于人群的中断时间序列分析。
Basic Clin Pharmacol Toxicol. 2022 Nov;131(5):306-310. doi: 10.1111/bcpt.13768. Epub 2022 Jul 16.
2
Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.他汀类药物对慢性肾脏病患者肾脏结局的影响:一项系统评价与Meta分析
PLoS One. 2015 Jul 7;10(7):e0132970. doi: 10.1371/journal.pone.0132970. eCollection 2015.
3
Chronic kidney disease and statin eligibility.慢性肾脏病与他汀类药物适应证。
J Clin Lipidol. 2021 Jan-Feb;15(1):173-180. doi: 10.1016/j.jacl.2020.10.004. Epub 2020 Oct 31.
4
Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline.慢性肾脏病中的脂质管理:《改善全球肾脏病预后组织 2013 年临床实践指南》概要。
Ann Intern Med. 2014 Feb 4;160(3):182. doi: 10.7326/M13-2453.
5
Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis.他汀类药物对肾脏疾病结局的影响:系统评价和荟萃分析。
Am J Kidney Dis. 2016 Jun;67(6):881-92. doi: 10.1053/j.ajkd.2016.01.016. Epub 2016 Feb 20.
6
Association between intensity of statin therapy and mortality in persons with chronic kidney disease.他汀类药物治疗强度与慢性肾脏病患者死亡率的关系。
Nephrol Dial Transplant. 2020 Feb 1;35(2):312-319. doi: 10.1093/ndt/gfy237.
7
Using pharmacists to improve risk stratification and management of stage 3A chronic kidney disease: a feasibility study.利用药剂师改善3A期慢性肾脏病的风险分层与管理:一项可行性研究
BMC Nephrol. 2016 Nov 8;17(1):168. doi: 10.1186/s12882-016-0383-7.
8
Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?他汀类药物可改善慢性肾病患者的蛋白尿和肾小球滤过率降低情况,进一步降低心血管风险。这是真还是假?
Expert Opin Pharmacother. 2015;16(10):1449-61. doi: 10.1517/14656566.2015.1053464. Epub 2015 Jun 3.
9
Statins in chronic kidney disease: cardiovascular risk and kidney function.他汀类药物在慢性肾脏病中的应用:心血管风险与肾功能。
Postgrad Med. 2014 Jan;126(1):29-36. doi: 10.3810/pgm.2014.01.2722.
10
Cardiovascular Risk Stratification and Appropriate Use of Statins in Patients with Chronic Kidney Disease According to Different Strategies.根据不同策略对慢性肾脏病患者进行心血管风险分层及他汀类药物的合理使用
High Blood Press Cardiovasc Prev. 2022 Sep;29(5):435-443. doi: 10.1007/s40292-022-00531-8. Epub 2022 Jun 25.

引用本文的文献

1
Statin use and acute kidney injury among hospitalized chronic kidney disease patients: a retrospective cohort study.住院慢性肾脏病患者使用他汀类药物与急性肾损伤:一项回顾性队列研究。
Front Med (Lausanne). 2025 Sep 1;12:1639130. doi: 10.3389/fmed.2025.1639130. eCollection 2025.
2
Rate and Risk Factors of Acute Myocardial Infarction after Debut of Chronic Kidney Disease-Results from the KidDiCo.慢性肾脏病初发后急性心肌梗死的发生率及危险因素——KidDiCo研究结果
J Cardiovasc Dev Dis. 2022 Nov 9;9(11):387. doi: 10.3390/jcdd9110387.

本文引用的文献

1
Effects of statins on mitochondrial pathways.他汀类药物对线粒体途径的影响。
J Cachexia Sarcopenia Muscle. 2021 Apr;12(2):237-251. doi: 10.1002/jcsm.12654. Epub 2021 Jan 29.
2
Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study.慢性肾脏病患者的用药模式及多重用药负担:德国慢性肾脏病研究
Clin Kidney J. 2019 May 24;12(5):663-672. doi: 10.1093/ckj/sfz046. eCollection 2019 Oct.
3
Statin Toxicity.他汀类药物毒性。
Circ Res. 2019 Jan 18;124(2):328-350. doi: 10.1161/CIRCRESAHA.118.312782.
4
Sixteen years of creatinine measurements among 460 000 individuals-The Funen Laboratory Cohort (FLaC), a population-based pharmacoepidemiological resource to study drug-induced kidney disease.46 万人的 16 年肌酐测量数据——凡恩实验室队列(FLaC),一个基于人群的药物流行病学资源,用于研究药物引起的肾脏疾病。
Basic Clin Pharmacol Toxicol. 2019 May;124(5):582-590. doi: 10.1111/bcpt.13167. Epub 2018 Dec 18.
5
Impact of the application of the JNC 8 and KDIGO-2013 guidelines on hypertension and lipid control in a Nephrology outpatient clinic.
Nefrologia (Engl Ed). 2018 Jul-Aug;38(4):379-385. doi: 10.1016/j.nefro.2017.10.003.
6
Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018.他汀类药物会诱发还是预防急性肾损伤和慢性肾脏病:2018年最新综述
J Transl Int Med. 2018 Mar 28;6(1):21-25. doi: 10.2478/jtim-2018-0005. eCollection 2018 Mar.
7
Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction.他汀类药物不耐受与心肌梗死后冠心病事件和全因死亡率的关系。
J Am Coll Cardiol. 2017 Mar 21;69(11):1386-1395. doi: 10.1016/j.jacc.2016.12.036.
8
Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association.他汀类药物与心血管疾病患者使用的特定药物之间具有临床意义的药物相互作用的管理建议:美国心脏协会的科学声明
Circulation. 2016 Nov 22;134(21):e468-e495. doi: 10.1161/CIR.0000000000000456. Epub 2016 Oct 17.
9
Prevalence and recognition of chronic kidney disease in Stockholm healthcare.斯德哥尔摩医疗保健中慢性肾脏病的患病率与认知情况
Nephrol Dial Transplant. 2016 Dec;31(12):2086-2094. doi: 10.1093/ndt/gfw354. Epub 2016 Oct 13.
10
Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates.实施KDIGO血脂管理指南需要大幅提高他汀类药物的处方率。
Kidney Int. 2015 Dec;88(6):1411-1418. doi: 10.1038/ki.2015.246. Epub 2015 Sep 2.